Comparative behavioral and neurochemical studies of R- and S-1-methyl-1,2,3,4-tetrahydroisoquinoline stereoisomers in the rat

Pharmacological Reports

Volumn 64, Issue 4, 2012, Pages 857-869

  Wa̧sik, Agnieszka ^a   Romańska, Irena ^a   Michaluk, Jerzy ^a   Antkiewicz Michaluk, Lucyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

1MeTIQ stereoisomers; Dopamine metabolism; Dopamine release; Ex vivo HPLC study; In vivo microdialysis study; Rat brain structures

Indexed keywords

1 METHYL 1,2,3,4 TETRAHYDROISOQUINOLINE; 3 O METHYLDOPAMINE; AMINE OXIDASE (FLAVIN CONTAINING); CENTRAL NERVOUS SYSTEM AGENTS; DOPAMINE; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CELL METABOLISM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; ENZYME INHIBITION; EX VIVO STUDY; EXPLORATORY BEHAVIOR; IN VIVO STUDY; LOCOMOTION; LOW DRUG DOSE; MALE; METABOLITE; NERVE CELL; NERVE ENDING; NONHUMAN; NUCLEUS ACCUMBENS; RACEMIC MIXTURE; RAT; SINGLE DRUG DOSE; STEREOISOMERISM;

EID: 84867663899     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70880-0     Document Type: Article

References (38)

1. Abe K, Taguchi K, Wasai I, Utsunomiya I, Shinohara T, Miyatake T, Sano T: Stereoselective effect of (R) - and S-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease. Brain Res Bull, 2001, 56, 55-60. (Pubitemid 32962939)
2. Abe K, Saitoh T, Horiguchi Y, Utsunomiya I, Taguchi K: Synthesis and neurotoxicity of tetrahydroisoquinoline derivatives for studying Parkinson's disease. Biol Pharm Bull, 2005, 28, 1355-1362. (Pubitemid 41379680)
3. Adams JD Jr, Odunze IN: Oxygen free radicals and Parkinson's disease. Free Radic Biol Med, 1991, 10, 161-169.
4. Antkiewicz-Michaluk L, Filip M, Michaluk M, Romańska I, Przegaliński E, Vetulani J: An endogenous neuroprotectant substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats. J Neural Transm, 2007, 114, 307-317. (Pubitemid 46328651)
5. Antkiewicz-Michaluk L, Łazarewicz JW, Patsenka A, Kajta M, Ziemińska E, Salińska E, Wa̧sik A et al.: The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properities and inhibition of glutamate-induced excitotoxicity. J Neurochem, 2006, 97, 846-856.
6. Antkiewicz-Michaluk L, Michaluk J, Mokrosz M, Romańska I, Lorenc-Koci E, Otha S, Vetulani J: Different action on dopamine catabolic pathways of two endogenous 1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties. J Neurochem, 2001, 78, 100-108. (Pubitemid 32622592)
7. Antkiewicz-Michaluk L, Michaluk J, Romańska I, Papla I, Vetulani I: Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol. J Neural Transm, 2000, 107, 1009-1019.
8. Antkiewicz-Michaluk L, Wardas J, Michaluk J, Romańska I, Bojarski A, Vetulani J: Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int J Neuropsychopharmacol, 2004, 7, 155-163. (Pubitemid 38823282)
9. Antkiewicz-Michaluk L, Wa̧sik A, Romańska I, Bojarski A, Michaluk J: Both stereoselective R- and S-1-methyl-1,2,3,4- tetrahydroisoquinoline enantiomers protect striatal terminals against rotenone-induced suppression of dopamine release. Neurotox Res, 2011, 20, 134-149.
10. Asanuma M, Miyazaki I, Ogawa N: Dopamine or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res, 2003, 5, 165-176.
11. Ayala A, Parrado J, Cano J, Machado A: Reduction of 1-methyl-1,2,3,4- tetrahydroisoquinoline level in substantia nigra of aged rat. Brain Res, 1994, 638, 334-336. (Pubitemid 24063322)
12. Carillo MC, Minami C, Kitani K, Maruyama W, Ohashi K, Yamamoto T, Naoi M: Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system of the rat. Life Sci, 2000, 67, 577-585. (Pubitemid 30431547)
13. Dykens JA: Free radicals and mitochondria dysfunction in exitotoxicity and neurodegenerative disease. In: Cell death and diseases of nervous system. Humana Press, Totowa, NJ, 1999, 45-68.
14. Garzon J, Fuentes J, Del Rio J: Effect of selective monoamine oxidase inhibitor drugs on morphine tolerance and physical dependence in mice. Neuropharmacology, 1979, 18, 531-536. (Pubitemid 9195701)
15. Gerlach M, Riederer P: Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm, 1996, 103, 987-1041. (Pubitemid 26383833)
16. Grasing K, He S: Effects of high-dose of selegiline on morphine reinforcement and precipitated withdrawal in dependent rats. Behav Pharmacol, 2005, 16, 1-13. (Pubitemid 40354361)
17. Igarashi K, Sugiyama Y, Kasuya F, Saiki K, Yamakawa T, Ohta S: Determination of 1-methyl-1,2,3,4-tetrahydroisoquinoline in mouse brain after treatment with haloperidol by gas chromatography-selected ion monitoring. J Chromatogr B Biomed Sci Appl, 1999, 731, 53-58. (Pubitemid 29376413)
18. Ishiwata K, Koyanagi Y, Abe K, Kawamura K, Taguchi K, Saitoh T, Toda J et al.: Evaluation of neurotoxicity of TIQ andMPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D2 receptors in the mouse striatum. J Neurochem, 2001, 79, 868-876. (Pubitemid 33086524)
19. Kohno M, Otha S, Hirobe M: Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline as novel endogenous amines in rat brain. Biochem Biophys Res Commun, 1986, 140, 448-454. (Pubitemid 17190044)
20. Kotake Y, Tasaki Y, Makino Y, Otha S, Hirobe M: 1-Benzyl-1,2,3,4- tetrahydroisoquinoline as a parkinson-ism- inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF. J Neurochem, 1995, 65, 2633-2638.
21. Kotake Y, Taguchi R, Okuda K, Sekiya Y, Tasaki Y, Hirobe M, Ohta S: Neuroprotective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on cultured rat mesencephalic neurons in the presence or absence of various neurotoxins. Brain Res, 2005, 1033, 143-150. (Pubitemid 40193408)
22. Kupsch A, Sautter J, Gotz ME, Breithaupt W, Schwarz J, Youdim MBH, Riederer P et al.: Monoamine oxidaseinhibition and MPTP-induced neurotoxicity in the nonhuman primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm, 2001, 108, 985-1009. (Pubitemid 32802096)
23. Maruyama W, Yamamoto T, Kitani K, Carrillo MC, Youdim M, Naoi M: Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech Ageing Dev, 2000, 116, 181-191.
24. Miller J, Selhub J, Joseph J: Oxidative damage caused by free radicals produced during catecholamine autooxidation: protective effects of O-methylation and melatonin. Free Radic Biol Med, 1996, 21, 241-249. (Pubitemid 26255201)
25. Montgomery S, Hansen T, Kasper S: Efficacy of escitalopram compared to citalopram: a meta-analysis. Int J Neuropsychopharmacol, 2011, 14, 261-268.
26. Nappi AJ, Vass E: Hydroxyl radical formation via iron-mediated Fenton chemistry is inhibited by methylated catechols. Biochim Biophys Acta, 1998, 1425, 159-167. (Pubitemid 28479722)
27. Ohta S, Kohno M, Makino Y, Tachikawa O, Hirobe M: Tetrahydroisoquinoline and 1-methyltetrahydroisoquinoline are present in the human brain: relation to Parkinson's disease. Biomed Res, 1987, 8, 453-456.
28. Okuda K, Kotake Y, Ohta S: Neuroprotective or neurotoxic activity of 1-methyl-1,2,3,4-tetrahydroisoquinoline and related compounds. Bioorg Med Chem Lett, 2003, 13, 2853-2855. (Pubitemid 37386238)
29. Olanow CW: An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol, Suppl, 1992, 32, S2-S9.
30. Parrado J, Absi E, Ayala A, Castano A, Cano J, Machado A: The endogenous amine 1-methyl-1,2,3,4-tetrahydroisoquinoline prevents the inhibition of complex I of the respiratory chain produced by MPP+ . J Neurochem, 2000, 75, 65-71. (Pubitemid 30418170)
31. Patsenka A, Antkiewicz-Michaluk L: Inhibition of rodent brain monoamine oxidase and tyrosine hydroxylase by endogenous compounds - 1,2,3,4-tetrahydro- isoquinoline alkaloids. Pol J Pharmacol, 2004, 56, 727-734. (Pubitemid 40287474)
32. Paxinos G, Watson CH: The rat brain in stereotaxic coordinates. Academic Press, London, 1998.
33. Sanchez-Blazquez P, Boronat BA, Olmos G, Garcia- Sevilla JA, Garzon J: Activation of 1(2)-imidazoline receptors enchances supraspinal morphine analgesia in mice: a model detect agonist and antagonist activities at these receptors. Br J Pharmacol, 2000, 130, 146-152. (Pubitemid 30248438)
34. Smith SW: Chiral toxicology: it's the same thing ...only different. Toxicol Sci, 2009, 110, 4-30.
35. Tasaki Y, Makino Y, Ohta S, Hirobe M: 1-Methyl- 1,2,3,4- tetrahydroisoquinoline, decreasing in 1-methyl- 4-phenyl-1,2,3,6- tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities. J Neurochem, 1991, 57, 1940-1943. (Pubitemid 21922843)
36. Wa̧sik A, Romańska I, Antkiewicz-Michaluk L: The effect of an endogenous compoud 1-methyl-1,2,3,4-tetrahydroisoquinoline on morphine-induced analgesia, dependence and neurochemical changes in dopamine metabolism in rat brain structures. J Physiol Pharmacol, 2007, 58, 235-252. (Pubitemid 47026559)
37. Yamakawa T, Kotake Y, Fuijtani M, Shintani H, Makino Y, Ohta S: Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain. Neurosci Lett, 1999, 26, 276, 68-70. (Pubitemid 29525527)
38. Yamakawa T, Ohta S: Isolation of 1-methyl-1,2,3,4-tetrahydroisoquinoline- synthesizing enzyme from rat brain: a possible Parkinson's disease-preventing enzyme. Biochem Biophys Res Commun, 1997, 236, 676-681. (Pubitemid 27384688)